15 дек. 2023 г. · Casgevy (exagamglogene autotemcel) is indicated for the treatment of transfusion‐dependent beta thalassemia and severe sickle cell disease in patients 12 years ...

10 окт. 2023 г. · Lyfnua is a medicine used to treat adults with chronic (long-term) cough which is unexplained or for which other treatments have not worked. Overview · Product information · Authorisation details

LYFGENIA is a one-time gene therapy to treat sickle cell disease in individuals 12 years of age or older and a history of vaso-occlusive events (VOEs). About LYFGENIA · Learn how LYFGENIA works · Steps to Treatment · FAQs

26 сент. 2024 г. · The European Medicines Agency (EMA) recommended on September 26, 2024, that the marketing authorization for Pfizer's drug Oxbryta (voxelotor) be suspended.

29 янв. 2024 г. · Lyfgenia uses a lentiviral vector (gene delivery vehicle) for genetic modification. Gene therapy involves introducing, removing or editing ...

8 дек. 2023 г. · The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years ...

Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older.

22 мар. 2024 г. · With lovotibeglogene autotemcel (Lyfgenia), CD34+ haematopoietic stem cells obtained from the patient were transduced ex vivo to produce a ... INTRODUCTION · FIRST-IN-CLASS DRUGS BY...

8 дек. 2023 г. · LYFGENIA is a one-time ex-vivo lentiviral vector gene therapy approved for the treatment of patients 12 years of age or older with sickle cell ...

10 июл. 2024 г. · LYFGENIA is indicated for treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events ...